Last reviewed · How we verify
Intravenous infusion of ketamine
Intravenous infusion of ketamine is a Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous infusion of ketamine |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Experienced sedation beyond postanesthesia care unit
- Oxygen requirement beyond postanesthesia care unit
- Experienced vomiting
- Numbness
- Dissociation
- Hypomania
- Drowsiness,fatigue
- Dizziness
- Visual disturbance
- Severe bradycardia
- Lightheadedness
- Gastrointestinal disturbance
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (PHASE3)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. (NA)
- Pilot Study of RR-HNK in OCD (PHASE1, PHASE2)
- University of Iowa Interventional Psychiatry Service Patient Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous infusion of ketamine CI brief — competitive landscape report
- Intravenous infusion of ketamine updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about Intravenous infusion of ketamine
What is Intravenous infusion of ketamine?
Intravenous infusion of ketamine is a Small molecule drug developed by University Hospital, Basel, Switzerland.
Who makes Intravenous infusion of ketamine?
Intravenous infusion of ketamine is developed by University Hospital, Basel, Switzerland (see full University Hospital, Basel, Switzerland pipeline at /company/university-hospital-basel-switzerland).
What development phase is Intravenous infusion of ketamine in?
Intravenous infusion of ketamine is in Phase 1.
What are the side effects of Intravenous infusion of ketamine?
Common side effects of Intravenous infusion of ketamine include Experienced sedation beyond postanesthesia care unit, Oxygen requirement beyond postanesthesia care unit, Experienced vomiting, Numbness, Dissociation, Hypomania.